Italia markets close in 2 hours 19 minutes
FTSE MIB
33.421,27 -285,94 (-0,85%) Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
80,97 +0,14 (+0,17%) Bitcoin EUR
57.530,30 +322,12 (+0,56%)
NBIX Sep 2024 140.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 11:55AM EDT. Mercato aperto.
| Chiusura precedente | 9,80 |
| Aperto | 9,80 |
| Denaro | 0,00 |
| Domanda | 0,00 |
| Prezzo d'esercizio | 140,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 9,80 - 9,80 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1,02k |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.